We completed enrollment in September 2017. In total 26 patients received Cirmtuzumab. The 20 mg/kg cohort included 6 patients, as per standard 3+3 design. There were no dose-limiting toxicities, and so this dose is determined to be safe and well-tolerated. Patients had a delayed time to progression that correlated with Cirmtuzumab’s long plasma half-life.The clinical trial has now completed enrollment with no evidence of dose limiting toxicity at doses up to 20 mg/kg. We will now initiate a Phase 1b/2 trial in combination with ibrutinib for patients with CLL under the auspices of a CLIN2 grant and in collaboration with Oncternal Therapeutics.